middle.news
Neurotech Starts Pivotal Phase 3 Trial for NTI164 Autism Treatment
8:51am on Monday 21st of September, 2026 AEST
•
Biotechnology
Read Story
Neurotech Starts Pivotal Phase 3 Trial for NTI164 Autism Treatment
8:51am on Monday 21st of September, 2026 AEST
Key Points
First patient dosed in the Beyond Harmony Phase 3 study
Up to 200 children planned across six Australian sites
Randomised, double-blind, placebo-controlled adaptive trial design
Program builds on the earlier 54-patient HARMONY study
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE